KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Accumulated Expenses: 2009-2024

Historic Accumulated Expenses for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $10.1 million.

  • Rigel Pharmaceuticals' Accumulated Expenses rose 27.02% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 27.02%. This contributed to the annual value of $10.1 million for FY2024, which is 16.86% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Accumulated Expenses of $10.1 million as of FY2024, which was up 16.86% from $8.7 million recorded in FY2023.
  • Rigel Pharmaceuticals' Accumulated Expenses' 5-year high stood at $10.7 million during FY2021, with a 5-year trough of $8.7 million in FY2023.
  • In the last 3 years, Rigel Pharmaceuticals' Accumulated Expenses had a median value of $8.9 million in 2022 and averaged $9.2 million.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Accumulated Expenses dropped by 17.06% in 2022 and then rose by 16.86% in 2024.
  • Rigel Pharmaceuticals' Accumulated Expenses (Yearly) stood at $9.6 million in 2020, then climbed by 11.45% to $10.7 million in 2021, then fell by 17.06% to $8.9 million in 2022, then decreased by 2.14% to $8.7 million in 2023, then grew by 16.86% to $10.1 million in 2024.